Stallergenes Greer: Positive Results of EfficAPSI Real-World

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy

Related Keywords

France , Czech Republic , Frolund , Midtjylland , Denmark , United States , Paris , France General , Copenhagen , Køavn , Switzerland , Czech , French , Henrik Nielsen , Michele Antonelli , Catherine Kress , Pascal Demoly , Philippe Devillier , Bertrand Delaisi , Mathieu Molimard , Stallergenes Greer , Jean Fran , World Health Organization , Stallergenes Greer International , Diderot University France , Montpellier University Hospital France , European Academy Of Allergy , Greer Laboratories Inc , Thoracic Oncology Department , Clinical Immunology , Professor Pascal Demoly , Montpellier University Hospital , Chief Executive Officer , Internal Medicine , Paris Diderot University , Greer International , Greer Laboratories , Allergy Clin , Copenhagen Allergy , Shinj W , Suej H , Songt W , Allergy Asthma , Stallergenes , Career , Positive , Results , Fficapsi , Meal , World , Study , Confirm , Significant , Benefit , Sublingual , Liquid , Treatment , Onset , Worsening , Asthma , Patients , Ith , Aallergic , Rhinitis ,